New Treatment Options in Chronic GVHD

Corey Cutler, MD, MPH, FRCPC, provides an overview of graft vs host disease and some of the factors that may put patients at higher risk.

Expert insight on prophylaxis in graft vs host disease, with a focus on specific pharmacologics and the overall efficacy of prophylactic strategies.

A comprehensive review of the treatment armamentarium for patients with chronic graft vs host disease.

Corey Cutler, MD, MPH, FRCPC, reviews the study design and results of REACH-2, which tested ruxolitinib in patients with steroid-refractory acute GVHD.

Expert insight on the study design and results of REACH-3, which tested ruxolitinib in patients with steroid-refractory chronic GVHD.

Closing out his discussion on chronic GVHD, Corey Cutler, MD, MPH, FRCPC, discusses belumosudil and how all 3 newly approved agents fit into the evolving treatment landscape.